Clinical characteristics and lung and cardiac function parameters of patients conditioned with BEAM or high-dose melphalan prior to auto-HSCT
| Variables . | BEAM (n = 334) . | MEL (n = 295) . |
|---|---|---|
| Patient characteristics | ||
| Age at diagnosis, median (range), y | 54.3 (17-78) | 57.2 (29-74) |
| Age at auto-HSCT, median (range), y | 56.3 (19-78) | 58.6 (29-74) |
| Females | 128 (38) | 120 (41) |
| KPS ≤ 80% | 89 (28) | 109 (39) |
| Pulmonary function tests prior to auto-HSCT | 320 (96) | 281 (95) |
| FEV1, % of predicted, median (range) | 91 (34-145) | 89 (35, 136) |
| FEV1/FVC ratio, median (range) | 0.80 (0.45-0.97) | 0.79 (0.42, 1.15) |
| MEF50, % of predicted, median (range) | 67 (11-173) | 62 (10, 165) |
| MEF25, % of predicted, median (range) | 38 (4-193) | 34 (5, 165) |
| DLCOcSB, % of predicted, median (range) | 77 (29-126) | 79 (35, 116) |
| RV, % of predicted, median (range) | 105 (36-249) | 104 (31-273) |
| RV/TLC ratio, median (range) | 0.35 (0.15-1.16) | 0.36 (0.15-0.69) |
| TLC, % of predicted, median (range) | 93 (54-134) | 93 (41-132) |
| Arterial CO2 mm Hg absolute, median (range) | 36 (25-52) | 36 (25-46) |
| Arterial O2 mm Hg absolute, median (range) | 81 (55-102) | 78 (56-97) |
| Transthoracic heart echography | 316 (95) | 281 (95) |
| EF 60-65% | 76 (23) | 62 (21) |
| EF 55-59% | 194 (58) | 184 (62) |
| EF 50-54% | 28 (8) | 21 (7) |
| EF ≤ 49% | 18 (5) | 14 (5) |
| Disease characteristics | ||
| Disease | ||
| B-cell NHL | 222 (68) | |
| T-cell NHL | 46 (13) | |
| Hodgkin lymphoma | 34 (9) | |
| MM | 8 (3) | 295 (100) |
| ALL | 4 (1) | |
| Burkitt lymphoma | 16 (5) | |
| B symptoms at diagnosis | 118 (34.8) | |
| B-stage at diagnosis as Durie-Salmon criteria | — | 37 (14) |
| Progressive disease at auto-HSCT | 28 (8) | 18 (6) |
| Auto-HSCT characteristics, median (range) | ||
| Days on the ward after auto-HSCT | 14 (9-110) | 15 (10-67) |
| CD34+ cells transplanted (×106 per kg bw) | 6.0 (0.15-55.6) | 5.2 (2.14-27.2) |
| Day of engraftment | ||
| Neutrophils | 10 (0-29) | 11 (2-53) |
| Thrombocytes | 11 (0-52) | 11 (1-80) |
| Treatments post auto-HSCT | ||
| Chemotherapy post auto-HSCT | 77 (23) | 170 (58) |
| Radiotherapy post auto-HSCT | 43 (13) | 90 (30) |
| Second auto-HSCT | 12 (4) | 102 (35) |
| Allo-HSCT after auto-HSCT | 41 (12) | 58 (20) |
| Follow-up, median (range), mo | 52 (0.2-153) | 50 (0.6-149) |
| Variables . | BEAM (n = 334) . | MEL (n = 295) . |
|---|---|---|
| Patient characteristics | ||
| Age at diagnosis, median (range), y | 54.3 (17-78) | 57.2 (29-74) |
| Age at auto-HSCT, median (range), y | 56.3 (19-78) | 58.6 (29-74) |
| Females | 128 (38) | 120 (41) |
| KPS ≤ 80% | 89 (28) | 109 (39) |
| Pulmonary function tests prior to auto-HSCT | 320 (96) | 281 (95) |
| FEV1, % of predicted, median (range) | 91 (34-145) | 89 (35, 136) |
| FEV1/FVC ratio, median (range) | 0.80 (0.45-0.97) | 0.79 (0.42, 1.15) |
| MEF50, % of predicted, median (range) | 67 (11-173) | 62 (10, 165) |
| MEF25, % of predicted, median (range) | 38 (4-193) | 34 (5, 165) |
| DLCOcSB, % of predicted, median (range) | 77 (29-126) | 79 (35, 116) |
| RV, % of predicted, median (range) | 105 (36-249) | 104 (31-273) |
| RV/TLC ratio, median (range) | 0.35 (0.15-1.16) | 0.36 (0.15-0.69) |
| TLC, % of predicted, median (range) | 93 (54-134) | 93 (41-132) |
| Arterial CO2 mm Hg absolute, median (range) | 36 (25-52) | 36 (25-46) |
| Arterial O2 mm Hg absolute, median (range) | 81 (55-102) | 78 (56-97) |
| Transthoracic heart echography | 316 (95) | 281 (95) |
| EF 60-65% | 76 (23) | 62 (21) |
| EF 55-59% | 194 (58) | 184 (62) |
| EF 50-54% | 28 (8) | 21 (7) |
| EF ≤ 49% | 18 (5) | 14 (5) |
| Disease characteristics | ||
| Disease | ||
| B-cell NHL | 222 (68) | |
| T-cell NHL | 46 (13) | |
| Hodgkin lymphoma | 34 (9) | |
| MM | 8 (3) | 295 (100) |
| ALL | 4 (1) | |
| Burkitt lymphoma | 16 (5) | |
| B symptoms at diagnosis | 118 (34.8) | |
| B-stage at diagnosis as Durie-Salmon criteria | — | 37 (14) |
| Progressive disease at auto-HSCT | 28 (8) | 18 (6) |
| Auto-HSCT characteristics, median (range) | ||
| Days on the ward after auto-HSCT | 14 (9-110) | 15 (10-67) |
| CD34+ cells transplanted (×106 per kg bw) | 6.0 (0.15-55.6) | 5.2 (2.14-27.2) |
| Day of engraftment | ||
| Neutrophils | 10 (0-29) | 11 (2-53) |
| Thrombocytes | 11 (0-52) | 11 (1-80) |
| Treatments post auto-HSCT | ||
| Chemotherapy post auto-HSCT | 77 (23) | 170 (58) |
| Radiotherapy post auto-HSCT | 43 (13) | 90 (30) |
| Second auto-HSCT | 12 (4) | 102 (35) |
| Allo-HSCT after auto-HSCT | 41 (12) | 58 (20) |
| Follow-up, median (range), mo | 52 (0.2-153) | 50 (0.6-149) |
Unless other noted, data are n (%).
ALL, acute lymphoblastic leukemia; allo-HSCT, allogeneic hematopoietic stem cell transplantation; bw, body weight; EF, ejection fraction; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; MEF25, mid-expiratory flow 25% of vital capacity; MEF50, mid-expiratory flow 50% of vital capacity; MEL, high-dose melphalan; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; RV, residual volume; TLC, total lung capacity.